IL280046A - Compositions and methods relating to engineered constructs with an antigen-binding site FC targeted to CD38 - Google Patents

Compositions and methods relating to engineered constructs with an antigen-binding site FC targeted to CD38

Info

Publication number
IL280046A
IL280046A IL280046A IL28004621A IL280046A IL 280046 A IL280046 A IL 280046A IL 280046 A IL280046 A IL 280046A IL 28004621 A IL28004621 A IL 28004621A IL 280046 A IL280046 A IL 280046A
Authority
IL
Israel
Prior art keywords
engineered
compositions
antigen binding
binding domain
methods related
Prior art date
Application number
IL280046A
Other languages
English (en)
Hebrew (he)
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of IL280046A publication Critical patent/IL280046A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL280046A 2018-07-11 2021-01-10 Compositions and methods relating to engineered constructs with an antigen-binding site FC targeted to CD38 IL280046A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862696759P 2018-07-11 2018-07-11
US201862733036P 2018-09-18 2018-09-18
US201862744067P 2018-10-10 2018-10-10
PCT/US2019/041468 WO2020014526A2 (en) 2018-07-11 2019-07-11 Compositions and methods related to engineered fc-antigen binding domain constructs targeted to cd38

Publications (1)

Publication Number Publication Date
IL280046A true IL280046A (en) 2021-03-01

Family

ID=69141927

Family Applications (1)

Application Number Title Priority Date Filing Date
IL280046A IL280046A (en) 2018-07-11 2021-01-10 Compositions and methods relating to engineered constructs with an antigen-binding site FC targeted to CD38

Country Status (11)

Country Link
US (1) US20210269546A1 (https=)
EP (1) EP3820516A4 (https=)
JP (1) JP2021530498A (https=)
KR (1) KR20210044218A (https=)
CN (1) CN113194990A (https=)
AU (1) AU2019299973A1 (https=)
BR (1) BR112021000416A2 (https=)
CA (1) CA3106142A1 (https=)
IL (1) IL280046A (https=)
MX (1) MX2021000307A (https=)
WO (1) WO2020014526A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
CN118591388A (zh) * 2021-09-29 2024-09-03 摩德斯医疗股份有限公司 抗原结合多肽、抗原结合多肽复合物及其使用方法
CN115873127B (zh) * 2021-11-26 2026-04-10 深圳科兴药业有限公司 重组长效人生长激素融合蛋白及其制备方法和用途
EP4448585A4 (en) * 2021-12-17 2026-02-25 Modex Therapeutics Inc ANTIGEN-BINDING POLYPEPTIDE COMPLEXES CONTAINING EXTRACELLULAR DOMAINS OF TNFSF LIGANDS
WO2025229158A1 (en) * 2024-05-01 2025-11-06 Commit Biologics Aps Antibodies and antibody constructs against cd38

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140242081A1 (en) * 2011-07-18 2014-08-28 Micromet Ag Dosing regimens for treatment of cea-expressing cancers
EP2748197A2 (en) * 2011-08-26 2014-07-02 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
KR20200024345A (ko) * 2013-01-10 2020-03-06 젠맵 비. 브이 인간 IgG1 Fc 영역 변이체 및 그의 용도
AU2015358615B2 (en) * 2014-12-04 2021-08-05 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute myeloid leukemia
CA2994746A1 (en) * 2015-08-11 2017-02-16 Cellectis Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
WO2017151971A2 (en) * 2016-03-02 2017-09-08 Momenta Pharmaceuticals, Inc. METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
BR112018074056A2 (pt) * 2016-05-23 2019-03-06 Momenta Pharmaceuticals, Inc. composições e métodos relacionados a construtos de fc manipulados
CA3043251A1 (en) * 2016-12-09 2018-06-14 Gliknik Inc. Methods of treating inflammatory disorders with multivalent fc compounds

Also Published As

Publication number Publication date
MX2021000307A (es) 2021-09-08
CA3106142A1 (en) 2020-01-16
JP2021530498A (ja) 2021-11-11
KR20210044218A (ko) 2021-04-22
BR112021000416A2 (pt) 2021-04-06
US20210269546A1 (en) 2021-09-02
CN113194990A (zh) 2021-07-30
AU2019299973A1 (en) 2021-02-18
EP3820516A4 (en) 2022-04-20
WO2020014526A2 (en) 2020-01-16
WO2020014526A3 (en) 2020-02-20
EP3820516A2 (en) 2021-05-19

Similar Documents

Publication Publication Date Title
IL280046A (en) Compositions and methods relating to engineered constructs with an antigen-binding site FC targeted to CD38
EP3565595A4 (en) COMPOSITIONS AND METHODS ASSOCIATED WITH DOMAIN CONSTRUCTIONS OF BINDING TO MANIPULATED FC ANTIGEN
IL279998A (en) Compositions and methods relating to engineered constructs with an antigen-binding site-FC
IL286367A (en) Compositions and methods relating to engineered fc constructs
IL280014A (en) Compositions and methods relating to engineered constructs with an antigen-binding site FC targeting CTLA-4
IL263211A (en) Compositions and methods relating to engineered fc constructs
HUE050279T2 (hu) Béta-klotho 2-es doménjéhez kötõdõ antitestek és azok alkalmazási módszerei
SG10202107391YA (en) Compositions and methods related to engineered fc constructs
IL257458A (en) dpep-1 binding compositions and methods of use
IL280044A (en) Compositions and methods relating to engineered constructs with an antigen-binding site-FC
IL280038A (en) Compositions and methods relating to engineered constructs with an antigen-binding site FC targeting PD-L1
EP3820517A4 (en) COMPOSITIONS AND METHODS RELATED TO CCR4-TARGETED FC ANTIGEN-BINDING DOMAIN CONSTRUCTIONS
IL279999A (en) Compositions and methods relating to engineered constructs with an antigen-binding site-FC
IL279989A (en) Compositions and methods relating to engineered constructs with an antigen-binding site-FC
IL291465A (en) Compositions and methods relating to engineered fc-antigen binding region constructs targeted to cd38
HK40053037A (en) Compositions and methods related to engineered fc-antigen binding domain constructs targeted to cd38
HK40053032A (en) Compositions and methods related to engineered fc-antigen binding domain constructs
HK40053031A (en) Compositions and methods related to engineered fc-antigen binding domain constructs
HK40053033A (en) Compositions and methods related to engineered fc-antigen binding domain constructs
HK40053036A (en) Compositions and methods related to engineered fc-antigen binding domain constructs
ZA202002763B (en) Fuel additive compositions, and method of use thereof
HK40053238A (en) Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ccr4
HK40053035A (en) Compositions and methods related to engineered fc-antigen binding domain constructs targeted to pd-l1
HK40017013A (en) Compositions and methods related to engineered fc-antigen binding domain constructs
HK40053034A (en) Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ctla-4